MXCT vs VTR · rev $38.6M vs P/E 149, rev $4.92B
MaxCyte Inc (MXCT) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
MXCT currently screens at market cap $124.3M. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the MXCT and VTR stock pages for the full models.
Not investment advice.